Now that The Australian Special Opportunity Fund LP (ASOF) managed by The Lind partners have removed the possibility of a CR and at the same time confirmed the commercial potential of Recce's 327 synthetic antibiotic, it should be all upside from here! I would have preferred a shareholder CR with free attached option, however it is good that The Lind Partners have gotten on-board as they are known for their astute investments in small and mid-cap Biotech companies.
Now that The Australian Special Opportunity Fund LP (ASOF)...
Add RCE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
52.0¢ |
Change
-0.020(3.70%) |
Mkt cap ! $125.0M | |||
| Open | High | Low | Value | Volume |
| 53.0¢ | 53.0¢ | 52.0¢ | $3.189K | 6.064K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 27440 | 52.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 53.0¢ | 5961 | 2 |
View Market Depth
| Last trade - 10.41am 27/09/2024 (20 minute delay) ? |
| RCE (ASX) Chart |